Mereo BioPharma (MREO) Return on Capital Employed (2023 - 2025)
Mereo BioPharma (MREO) has disclosed Return on Capital Employed for 3 consecutive years, with 0.23% as the latest value for Q4 2025.
- Quarterly Return on Capital Employed rose 92.0% to 0.23% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.23% through Dec 2025, up 92.0% year-over-year, with the annual reading at 0.18% for FY2025, 101.0% up from the prior year.
- Return on Capital Employed for Q4 2025 was 0.23% at Mereo BioPharma, up from 0.9% in the prior quarter.
- The five-year high for Return on Capital Employed was 0.23% in Q4 2025, with the low at 0.9% in Q3 2025.
- Average Return on Capital Employed over 3 years is 0.54%, with a median of 0.64% recorded in 2024.
- The sharpest move saw Return on Capital Employed tumbled -43bps in 2024, then surged 92bps in 2025.
- Over 3 years, Return on Capital Employed stood at 0.26% in 2023, then crashed by -164bps to 0.69% in 2024, then skyrocketed by 133bps to 0.23% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.23%, 0.9%, and 0.8% for Q4 2025, Q3 2025, and Q2 2025 respectively.